Francis Burrows Biography and Net Worth

Insider of Kura Oncology

Francis Burrows, Ph.D., is a drug discovery and development scientist with over twenty years’ experience in small and large biotech companies. He serves as Senior Vice President of Translational Research at Kura Oncology. Throughout his career, he has focused on the biology of disease, primarily cancer, and the discovery, characterization and development of small molecule drugs. Dr. Burrows has founded two biotech startups, one of which, Conforma Therapeutics, was acquired by Biogen in 2006. As Senior Director of Oncology Discovery at Biogen, he was responsible for one clinical, two preclinical and four discovery programs and also initiated efforts to use Hsp90 inhibitors in neurodegenerative and autoimmune conditions. In 2008, he founded Aarden Pharmaceutical, and in 2009 he also took on the role of Head of Oncology Biology at Tragara Pharmaceuticals. He earned his Ph.D. in immunology and completed his training in London and Dallas working on antibody-based therapeutics for cancer.

What is Francis Burrows' net worth?: The estimated net worth of Francis Burrows is at least $300.25 thousand as of January 27th, 2026. Burrows owns 32,424 shares of Kura Oncology stock worth more than $300,246 as of March 11th. This net worth estimate does not reflect any other investments that Burrows may own. Learn More about Francis Burrows' net worth.
How do I contact Francis Burrows?: The corporate mailing address for Burrows and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Francis Burrows' contact information.
Has Francis Burrows been buying or selling shares of Kura Oncology?: Within the last three months, Francis Burrows has sold $11,091.06 in Kura Oncology stock. Most recently, Francis Burrows sold 1,311 shares of the business's stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a transaction totalling $11,091.06. Following the completion of the sale, the insider now directly owns 32,424 shares of the company's stock, valued at $274,307.04. Learn More on Francis Burrows' trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Teresa Bair (Chief Legal Officer), Francis Burrows (Insider), Thomas Doyle (SVP, Finance and Accounting), Kathleen Ford (Chief Operating Officer), Laura Johnson (Director), Mollie Leoni (Chief Medical Officer), Thomas Malley (Director), Brian Powl (Insider), Anthony Praill (CFO), Troy Wilson (President and Chief Executive Officer), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, Kura Oncology insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $410,000.00. In the last twelve months, insiders at the sold shares 20 times. They sold a total of 185,586 shares worth more than $1,752,908.02. The most recent insider tranaction occured on January, 27th when COO Kathleen Ford sold 1,813 shares worth more than $15,337.98. Insiders at Kura Oncology own 6.4% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 1/27/2026.

Francis Burrows Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/27/2026	Sell	1,311	$8.46	$11,091.06	32,424
12/18/2025	Sell	23,726	$9.78	$232,040.28	33,735

Francis Burrows Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $9.26

$9.20

$9.60

50 Day Range

MA: $8.71

$7.40

$10.39

2 Week Range

Now: $9.26

$5.41

$12.49

Volume

1,608,270 shs

Average Volume

1,590,089 shs

Market Capitalization

$817.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22